These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
240 related items for PubMed ID: 989642
1. Chemorheological studies of the effect of heparin on the course of coagulation. Overholser KA, Baysinger CB, Harris TR, Deveau T. Thromb Haemost; 1976 Apr 30; 35(2):447-59. PubMed ID: 989642 [Abstract] [Full Text] [Related]
2. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma. Bhargava AS, Heinick J, Schöbel C, Günzel P. Arzneimittelforschung; 1980 Apr 30; 30(6):993-6. PubMed ID: 7191280 [Abstract] [Full Text] [Related]
8. A new route of heparin administration--the lung. Kavanagh LW, Jaques LB. Arzneimittelforschung; 1976 Apr 30; 26(3):389-92. PubMed ID: 989334 [Abstract] [Full Text] [Related]
9. Laboratory observations and clinical implications of monitoring the effect of heparin by bioassay. Goodman TL, Todd ME, Goldsmith EI. Surg Gynecol Obstet; 1976 May 30; 142(5):673-85. PubMed ID: 1265607 [Abstract] [Full Text] [Related]
10. The monitoring of heparin administration by screening tests in experimental dogs. Mischke R, Jacobs C. Res Vet Sci; 2001 Apr 30; 70(2):101-8. PubMed ID: 11356088 [Abstract] [Full Text] [Related]
11. Control of heparin therapy with an activated partial thromboplastin time. Akkerman JW, Sixma JJ, Bouma BN. Neth J Med; 1973 Apr 30; 16(3):129-35. PubMed ID: 4575720 [No Abstract] [Full Text] [Related]
12. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, Buss DH, Prough DS, Cordell AR. J Thorac Cardiovasc Surg; 1990 Mar 30; 99(3):518-27. PubMed ID: 2308370 [Abstract] [Full Text] [Related]
13. Inhibition of clot formation process by treatment with the low-molecular-weight heparin nadroparin in patients with carotid artery disease undergoing angioplasty and stenting. A thromboelastography study on whole blood. Konstantinidis K, Gerasimidis T, Verdy E, Elalamy I, Samama MM, Gerotziafas GT. Thromb Haemost; 2007 Jan 30; 97(1):109-18. PubMed ID: 17200777 [Abstract] [Full Text] [Related]
14. [Changes in the adhesiveness of thrombocytes under the effect of anticoagulants]. Merkulov MF, Lakin KM, Fel'dbaum VA, Efimov VS. Farmakol Toksikol; 1968 Jan 30; 31(6):706-9. PubMed ID: 5713582 [No Abstract] [Full Text] [Related]
15. Thromboelastographic evaluation of mini-dose heparin in minor surgical procedures. Vernese NA, Spillert CR, Franco CD, Lazaro EJ. Am Surg; 1986 Feb 30; 52(2):112-3. PubMed ID: 3946934 [Abstract] [Full Text] [Related]
16. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats. Greene CE, Meriwether E. Am J Vet Res; 1982 Aug 30; 43(8):1473-7. PubMed ID: 7103231 [Abstract] [Full Text] [Related]
17. Platelet involvement in the activated coagulation time of heparinized blood. Moorehead MT, Westengard JC, Bull BS. Anesth Analg; 1984 Apr 30; 63(4):394-8. PubMed ID: 6367544 [Abstract] [Full Text] [Related]
18. The impact of tissue factor pathway inhibitor on coagulation kinetics determined by thrombelastography. Audu P, Nielsen VG, Armstead V, Powell G, Kim J, Kim L, Mehta M. Anesth Analg; 2006 Oct 30; 103(4):841-5. PubMed ID: 17000790 [Abstract] [Full Text] [Related]